MA53170A - Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 - Google Patents
Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1Info
- Publication number
- MA53170A MA53170A MA053170A MA53170A MA53170A MA 53170 A MA53170 A MA 53170A MA 053170 A MA053170 A MA 053170A MA 53170 A MA53170 A MA 53170A MA 53170 A MA53170 A MA 53170A
- Authority
- MA
- Morocco
- Prior art keywords
- interleukin
- activity inhibitors
- sulphonylurea compounds
- sulphonylurea
- compounds
- Prior art date
Links
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53170A true MA53170A (fr) | 2021-05-26 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053170A MA53170A (fr) | 2018-07-20 | 2019-07-19 | Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (fr) |
| EP (1) | EP3823726A1 (fr) |
| JP (1) | JP7411631B2 (fr) |
| KR (1) | KR20210034588A (fr) |
| CN (1) | CN112437683A (fr) |
| AR (1) | AR117617A1 (fr) |
| AU (1) | AU2019305095A1 (fr) |
| BR (1) | BR112021001012A2 (fr) |
| CA (1) | CA3104199A1 (fr) |
| CL (1) | CL2021000152A1 (fr) |
| CO (1) | CO2021000817A2 (fr) |
| CR (1) | CR20210024A (fr) |
| IL (1) | IL280139A (fr) |
| MA (1) | MA53170A (fr) |
| MX (1) | MX2021000660A (fr) |
| PE (1) | PE20211049A1 (fr) |
| PH (1) | PH12020552155A1 (fr) |
| SG (1) | SG11202012159TA (fr) |
| TW (1) | TW202019937A (fr) |
| WO (1) | WO2020018970A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7163293B2 (ja) | 2017-01-23 | 2022-10-31 | ジェネンテック， インコーポレイテッド | インターロイキン－１活性の阻害剤としての化学化合物 |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3668843A1 (fr) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3 |
| WO2019092171A1 (fr) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Nouveaux composés de sulfonamide carboxamide |
| CA3078195A1 (fr) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Nouveaux composes de sulfonamide carboxamide |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| PE20211811A1 (es) | 2018-07-20 | 2021-09-14 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| CA3178361A1 (fr) * | 2020-06-19 | 2021-12-23 | Emanuele Gabellieri | Derives de dihydrooxazole et de thiouree modulant la voie inflammatoire nlrp3 |
| US20250109126A1 (en) | 2021-12-22 | 2025-04-03 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| AU2023221635A1 (en) | 2022-02-21 | 2024-09-12 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN119998284A (zh) | 2022-07-28 | 2025-05-13 | Ac免疫有限公司 | 新化合物 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2025153625A1 (fr) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3 |
| WO2025153624A1 (fr) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3 |
| WO2025163069A1 (fr) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Nouveaux composés |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| BR9714328A (pt) * | 1997-01-29 | 2000-03-21 | Pfizer | da atividade de interleucina-1 |
| CA2383026A1 (fr) | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree |
| WO2003045400A1 (fr) | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Combinaison d'un inhibiteur d'il-1/18 avec un inhibiteur de tnf pour le traitement d'inflammations |
| MX341482B (es) * | 2010-02-22 | 2016-08-22 | Raqualia Pharma Inc | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| MY193765A (en) * | 2015-02-16 | 2022-10-27 | Univ Queensland | Sulfonylureas and related compounds and use of same |
| US11858922B2 (en) * | 2016-02-16 | 2024-01-02 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7050751B2 (ja) | 2016-04-18 | 2022-04-08 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
| JP7163293B2 (ja) * | 2017-01-23 | 2022-10-31 | ジェネンテック， インコーポレイテッド | インターロイキン－１活性の阻害剤としての化学化合物 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| WO2019008029A1 (fr) | 2017-07-07 | 2019-01-10 | Inflazome Limited | Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3 |
| HRP20220195T1 (hr) | 2017-07-07 | 2022-04-15 | Inflazome Limited | Novi spojevi sulfonamid karboksamida |
| EP3668843A1 (fr) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3 |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| CN111132974B (zh) | 2017-08-15 | 2023-11-21 | 英夫拉索姆有限公司 | 新颖的磺酰胺羧酰胺化合物 |
| EP3668601A1 (fr) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Nouveaux composés de sulfonamide carboxamide |
| EP3668840A1 (fr) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Nouveaux composés de sulfonamide carboxamide |
| EP3668862A1 (fr) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Nouveaux composés de sulfonamide carboxamide |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019043610A1 (fr) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | Nouveaux dérivés de sulfonylurées substitués |
| WO2019092172A1 (fr) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Nouveaux composés de sulfonamide carboxamide |
| WO2019092171A1 (fr) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Nouveaux composés de sulfonamide carboxamide |
| CA3078195A1 (fr) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Nouveaux composes de sulfonamide carboxamide |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CA3103664A1 (fr) | 2018-07-03 | 2020-01-09 | Novartis Ag | Methodes de traitement ou de selection d'un traitement pour un sujet resistant a un inhibiteur de tnf a l'aide d'un antagoniste de nlrp3 |
| JP2021529187A (ja) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Ｎｌｒｐモジュレータ |
| PE20211811A1 (es) | 2018-07-20 | 2021-09-14 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
| US10981918B2 (en) | 2018-07-20 | 2021-04-20 | Grünenthal GmbH | Further substituted triazolo quinoxaline derivatives |
| PE20211333A1 (es) | 2018-08-15 | 2021-07-22 | Inflazome Ltd | Compuestos de sulfonamidaurea novedosos |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020154321A1 (fr) | 2019-01-22 | 2020-07-30 | Novartis Inflammasome Research, Inc. | Composés et compositions pour traiter des états associés à une activité de nlrp |
| WO2021002887A1 (fr) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie |
-
2019
- 2019-07-19 CA CA3104199A patent/CA3104199A1/fr active Pending
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/fr not_active Ceased
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko not_active Withdrawn
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/fr active Pending
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es not_active Application Discontinuation
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7411631B2 (ja) | 2024-01-11 |
| CO2021000817A2 (es) | 2021-02-17 |
| CR20210024A (es) | 2021-02-22 |
| CN112437683A (zh) | 2021-03-02 |
| PH12020552155A1 (en) | 2021-07-05 |
| TW202019937A (zh) | 2020-06-01 |
| CL2021000152A1 (es) | 2021-07-09 |
| AR117617A1 (es) | 2021-08-18 |
| MX2021000660A (es) | 2021-03-25 |
| US11560391B2 (en) | 2023-01-24 |
| AU2019305095A1 (en) | 2020-12-17 |
| IL280139A (en) | 2021-03-01 |
| US20210261568A1 (en) | 2021-08-26 |
| CA3104199A1 (fr) | 2020-01-23 |
| EP3823726A1 (fr) | 2021-05-26 |
| SG11202012159TA (en) | 2021-01-28 |
| WO2020018970A1 (fr) | 2020-01-23 |
| KR20210034588A (ko) | 2021-03-30 |
| JP2021530536A (ja) | 2021-11-11 |
| BR112021001012A2 (pt) | 2021-04-20 |
| PE20211049A1 (es) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53170A (fr) | Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| MA53172A (fr) | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| EP3941898C0 (fr) | Composés fongicides | |
| EP3740487A4 (fr) | Composés benzamide | |
| EP3956033A4 (fr) | Composés bicycliques | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA52421A (fr) | Composés pharmaceutiques | |
| EP4054724A4 (fr) | Composés bifonctionnels | |
| MA52948A (fr) | Composés | |
| IL289767A (en) | Novel heteroaryl-triazole compounds as pesticides | |
| MA47308A (fr) | Composés chimiques comme inhibiteurs de l'activité interleukine-1 | |
| MA51669A (fr) | Composés | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| EP4061364A4 (fr) | Composés hétéroaryles | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA48765A (fr) | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub | |
| MA53003A (fr) | Composés | |
| EP3852745A4 (fr) | Composés destinés au traitement de certaines leucémies | |
| EP3678700A4 (fr) | Composés pour la réduction de la viscosité de formulations biologiques | |
| IL280598A (en) | 2,6-diamino pyridine compounds | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP4077318A4 (fr) | Composés | |
| MA54378A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| IL287736A (en) | Diamondoid compounds |